JP2010540564A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540564A5
JP2010540564A5 JP2010527251A JP2010527251A JP2010540564A5 JP 2010540564 A5 JP2010540564 A5 JP 2010540564A5 JP 2010527251 A JP2010527251 A JP 2010527251A JP 2010527251 A JP2010527251 A JP 2010527251A JP 2010540564 A5 JP2010540564 A5 JP 2010540564A5
Authority
JP
Japan
Prior art keywords
composition
eye
ocular
scaav
interfering rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078380 external-priority patent/WO2009046059A1/en
Publication of JP2010540564A publication Critical patent/JP2010540564A/ja
Publication of JP2010540564A5 publication Critical patent/JP2010540564A5/ja
Pending legal-status Critical Current

Links

JP2010527251A 2007-10-01 2008-10-01 自己相補的なaavが媒介する眼の障害を処置または予防するための干渉rna分子の送達 Pending JP2010540564A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97655207P 2007-10-01 2007-10-01
PCT/US2008/078380 WO2009046059A1 (en) 2007-10-01 2008-10-01 Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders

Publications (2)

Publication Number Publication Date
JP2010540564A JP2010540564A (ja) 2010-12-24
JP2010540564A5 true JP2010540564A5 (cg-RX-API-DMAC7.html) 2012-09-13

Family

ID=40042637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527251A Pending JP2010540564A (ja) 2007-10-01 2008-10-01 自己相補的なaavが媒介する眼の障害を処置または予防するための干渉rna分子の送達

Country Status (12)

Country Link
US (1) US20090087413A1 (cg-RX-API-DMAC7.html)
EP (1) EP2192926A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010540564A (cg-RX-API-DMAC7.html)
KR (1) KR20100061792A (cg-RX-API-DMAC7.html)
CN (1) CN101815536A (cg-RX-API-DMAC7.html)
AU (1) AU2008308784B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817937A2 (cg-RX-API-DMAC7.html)
CA (1) CA2694091A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001608A (cg-RX-API-DMAC7.html)
RU (1) RU2010117178A (cg-RX-API-DMAC7.html)
WO (1) WO2009046059A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000423B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
CN105821079B (zh) * 2010-04-23 2021-10-26 佛罗里达大学研究基金公司 用于治疗莱伯氏先天性黑蒙-1(lca1)的raav-鸟苷酸环化酶组合物及方法
CN103505743A (zh) 2012-06-21 2014-01-15 北京命码生科科技有限公司 含功能性microRNA/siRNA的细胞微粒子及其应用
EP4012035B1 (en) * 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
SG10201913430VA (en) * 2014-09-16 2020-03-30 Genzyme Corp Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
PL4012035T3 (pl) * 2014-09-16 2025-03-24 Genzyme Corporation Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
GB201809588D0 (en) * 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
EP4161583A1 (en) * 2020-06-05 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treating ocular diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2505700T3 (es) * 2000-06-01 2014-10-10 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
NZ545544A (en) * 2003-08-13 2009-04-30 Univ Illinois Silencing of TGF-beta receptor type II expression by sirna
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
AU2006223131A1 (en) * 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd RNA干擾(RNAi)所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用(二)
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
CA2650416A1 (en) * 2006-05-19 2007-11-29 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor .alpha.-related conditions
BRPI0715821A2 (pt) * 2006-08-24 2013-07-23 Alcon Res Ltd inibiÇço de gremlina mediada por rnai para tratamento de condiÇÕes relacionadas À iop
EP2137205A2 (en) * 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof

Similar Documents

Publication Publication Date Title
JP2010540564A5 (cg-RX-API-DMAC7.html)
RU2010117178A (ru) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
Kang et al. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges
Vicentini et al. Delivery systems and local administration routes for therapeutic siRNA
JP6924744B2 (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
CY1119765T1 (el) Ιοσωματιδια αδενο-συσχετιζομενου ιου με καψιδιο παραλλαγματος και μεθοδοι χρησης εξ' αυτων
JP2013537423A5 (cg-RX-API-DMAC7.html)
NZ588583A (en) Novel lipid formulations for nucleic acid delivery
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
JP2015517466A5 (cg-RX-API-DMAC7.html)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
RU2013122656A (ru) Композиции и способы доставки терапевтических средств
JP2011516422A5 (cg-RX-API-DMAC7.html)
JP2011516094A5 (cg-RX-API-DMAC7.html)
EA200970435A1 (ru) Лечение общих расстройств развития
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
US9006202B2 (en) Method and compositions for treating HIV infection
Tang et al. Advanced oxidation protein products induce hypertrophy and epithelial-to-mesenchymal transition in human proximal tubular cells through induction of endoplasmic reticulum stress
WO2009053937A3 (en) Nano-lipid-based carriers for targeted delivery of viral vectors and process for its production
CN108939074B (zh) 治疗再生障碍性贫血的方法和药物组合物
AR073800A1 (es) Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196
US11649457B2 (en) Methods for treating SARS-CoV-2 infection
US20240035035A1 (en) Compositions and methods for treating, ameliorating, and/or preventing viral infections
AU2022384619A1 (en) Pharmaceutical combinations for treatment of hbv
Lam et al. What is the future of siRNA therapeutics?